The drug will be produced at the groups formulations manufacturing facility at Baddi (Himachal Pradesh). Citing IMS data, the company said the estimated sales for Voriconazole tablets is USD 92.8 million as on March 2016. The Ahmedabad-based group now has ... Business Standard, 1 day ago
Zydus gets FDA nod to market anti-fungal drug - Smart Investor, 1 day ago
Zydus gets final USFDA nod to sell Voriconazole Tab - Hindu Business Line, 1 day ago
1 images for "zydus group"
The Zydus Group, a leading global healthcare provider, announced that new clinical data on Lipaglyn (Saroglitazar) will be presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress to be ...PharmaBiz, 2 days ago Two presentations highlighting Zydus drug Lipaglyn will be featured at the AACE Annual meeting Pharma Focus Asia, 2 days ago
New Delhi, May 13 () Zydus Cadila group firm Cadila Healthcare today reported a 10.93 per cent rise in net profit to Rs 388.7 crore for the March quarter and also received nod from its board to raise up to Rs 18,500 crore through issuance of shares ...Times of India, 1 week ago Cadila profit at Rs 389 cr; to raise up to Rs 18,500 cr The Freepress Journal, 1 week ago Zydus Wellness Q4 net profit at Rs.25.8 crore India Infoline, 2 weeks ago Cadila Q4 net up 11% to Rs 389 crore; to raise up to Rs 18,500 crore Economic Times, 1 week ago
More from: NDTV, NDTV Profit...and 4 other sources
Healthcare player, Zydus Group on Monday announced acquisition of Actibile from Albert David Limited through its flagship company, Cadila Healthcare Limited. The company has entered into a definitive agreement to acquire the gastroenterology segment, which is ...Business Line, 1 month ago Cadila Healthcare slips 1% despite FDA nod to Zydus India Infoline, 1 month ago Zydus gets rights to gastro drug Actibile Pharma Letter, 1 month ago Zydus buys gastro therapy brand, Actibile from Albert David PharmaBiz, 1 month ago
Ahmedabad-based pharma major Cadila Healthcare has acquired Actibile, a gastroenterology brand from Kothari Group company Albert David for an undisclosed sum. The deal will be financed through internal accruals.The company today said in a statement ...Smart Investor, 1 month ago Zydus Cadila buys gastrointestinal brand from Albert David VC Circle, 1 month ago Zydus Health Acquires Gastrointestinal Drug From Albert David NDTV, 1 month ago Zydus Health acquires gastro drug 'Actibile' from Albert David Economic Times, 1 month ago
Shares of Albert David Ltd, a mid-cap pharmaceutical company, are currently trading 5.69% higher at Rs. 310 after the company yesterday enter into a deal with Zydus Cadila to sell one of its brands Actibile. Since the yesterday's announcement, ...India Infoline, 1 month ago Albert David ends 7% higher on Rs. 55 cr deal with Zydus Cadila India Infoline, 1 month ago Upsurge! Alber David ends 7% higher on Zydus deal India Infoline, 1 month ago
Indian promoter groups' share is Rs 5,930 crore. The post-budget rush by companies to declare dividends and pay it to all shareholders before March 31 will result in total dividend payouts of about Rs 11,980 crore by about 155 firms, of which about Rs 5,930 ...Asian Age, 2 months ago 155 firms to pay Rs 12k cr dividend before March 31 The Financial Chronicle, 2 months ago
QYResearch Group This report Mainly covers the following product types The segment applications including Segment regions including (the separated region report can also be offered) USA China Europe South America Japan Africa ...MarketResearch.com, 1 month ago Global Measles Report 2016 - Pipeline Review of 10 Companies & Drug Profiles - Research and Markets 4 Traders, 13 hours ago Global Varicella Zoster (HHV-3) Infections Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Astellas Pharma, Merck, TSRL - Research and Markets Minyanville, 2 weeks ago Varicella Zoster (HHV-3) Infections 2016 Market Therapeutics H1 Pipeline Research Review Before It's News, 1 week ago
The global clinical trial will be carried out in 406 patients and is designed to compare the safety, efficacy and immunogenicity of MSB11022 versus blockbuster arthritis and psoriasis drug Humira in patients with moderate to severe chronic plaque ...GaBi Online, 2 months ago
/PRNewswire/ -- This report analyzes the worldwide markets for in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and ...Biotechgate, 1 hour ago
More from: , Minyanville...and 6 other sources
on your WebpageAdd Widget >Get your members hooked!